PET/CT molecular imaging in abdominal oncology

Abdominal Imaging

Volumn 29, Issue 3, 2004, Pages 388-397

  Stahl, A ^a   Wieder, H ^a   Wester, H J ^a   Piert, M ^a   Lordick, F ^a   Ott, K ^a   Rummeny, E ^a   Schwaiger, M ^a   Weber, W A ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE F 18; ACETIC ACID C 11; ARGINYLGLYCYLASPARTIC ACID; CARBON 11; CHOLINE C 11; COPPER; CYTOTOXIN; FLUORINE 18; FLUOROAZOMYCIN ARABINOFURANOSIDE F 18; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; INTEGRIN; IODINE 124; IODINE 131; LIPOCORTIN 5; METHIONINE C 11; PENTETREOTIDE IN 111; PHOSPHATIDYLSERINE; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TECHNETIUM 99M; THYMIDINE DERIVATIVE; TIRAPAZAMINE; TOSITUMOMAB I 131; TRACER; UNCLASSIFIED DRUG; UNINDEXED DRUG; YTTRIUM 90;

ABDOMINAL TUMOR; APOPTOSIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DOSIMETRY; DRUG UPTAKE; GASTROINTESTINAL TUMOR; GENE THERAPY; HUMAN; HYPOXIA; ISOTOPE LABELING; LYMPHOMA; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; RADIOIMMUNOTHERAPY; REVIEW; TUMOR CELL; TUMOR DIAGNOSIS; URINARY EXCRETION;

EID: 2342562519     PISSN: 09428925     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00261-003-0113-z     Document Type: Review

References (65)

1. Shields AF, Grierson JR, Dohmen BM, et al. (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4:1334-1336
2. de Jong IJ, Pruim J, Elsinga PH, et al. (2002) Visualization of prostate cancer with 11C-choline positron emission tomography. Eur Urol 42: 18-23
3. Wester HJ, Schottelius M, Scheidhauer K, et al. (2003) PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel (18)F-labelled, carbohydrated analogue of octreotide. Eur J Nucl Med Mol Imaging 30:117-122
4. Haubner R, Wester HJ, Burkhart F, et al. (2001) Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 42:326-336
5. Hany TF, Steinert HC, Goerres GW, et al. (2002) PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology 225:575-581
6. Israel O, Mor M, Gaitini D, et al. (2002) Combined functional and structural evaluation of cancer patients with a hybrid camera-based PET/CT system using (18)F-FDG. J Nucl Med 43:1129-1136
7. Lardinois D, Weder W, Hany TF, et al. (2003) Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348:2500-2507
8. Hofer C, Laubenbacher C, Block T, et al. (1999) Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 36:31-35
9. Torizuka T, Tamaki N, Inokuma T, et al. (1995) In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 36:1811-1817
10. Bender H, Schomburg A, Albers P, et al. (1997) Possible role of FDG-PET in the evaluation of urologic malignancies. Anticancer Res 17:1655-1660
11. Berger KL, Nicholson SA, Dehdashti F, et al. (2000) FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR 174:1005-1008
12. Stahl A, Ott K, Weber WA, et al. (2003) FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 30:288-295
13. Weber WA, Wester HJ, Grosu AL, et al. (2000) O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 27:542-549
14. Wieder H, Ott K, Zimmermann F, et al. (2002) PET imaging with [11C]methyl-L-methionine for therapy monitoring in patients with rectal cancer. Eur J Nucl Med Mol Imaging 29:789-796
15. Nunez R, Macapinlac HA, Yeung HW, et al. (2002) Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 43:46-55
16. de Jong IJ, Pruim J, Elsinga PH, et al. (2002) Visualisation of bladder cancer using (11)C-choline PET: first clinical experience. Eur J Nucl Med Mol Imaging 29:1283-1288
17. de Jong IJ, Pruim J, Elsinga PH, et al. (2003) Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 44:331-335
18. Oyama N, Miller TR, Dehdashti F, et al. (2003) 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 44:549-555
19. Waldherr C, Pless M, Maecke HR, et al. (2002) Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTA-TOC. J Nucl Med 43:610-616
20. Hofmann M, Maecke H, Borner R, et al. (2001) Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 28:1751-1757
21. Ugur O, Kothari PJ, Finn RD, et al. (2002) Ga-66 labeled somatostatin analogue DOTA-DPhel-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol 29:147-157
22. Rosch F, Herzog H, Stolz B, et al. (1999) Uptake kinetics of the somatostatin receptor ligand [86Y]DOTA-DPhel-Tyr3-octreotide ([86Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue. Eur J Nucl Med 26:358-366
23. Prasad SR, Jhaveri KS, Saini S, et al. (2002) CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations. Radiology 225:416-419
24. Tsuchida Y, Therasse P (2001) Response evaluation criteria in solid tumors (RECIST): new guidelines. Med Pediatr Oncol 37:1-3
25. Buyse M, Thirion P, Carlson RW, et al. (2000) Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 356:373-378
26. Miller AB, Hoogstraten B, Staquet M, et al. (1981) Reporting results of cancer treatment. Cancer 47:207-214
27. Moertel CG, Hanley JA (1976) The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer 38:388-394
28. Findlay M, Young H, Cunningham D, et al. (1996) Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol 14:700-708
29. Brucher BL, Weber W, Bauer M, et al. (2001) Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 233:300-309
30. Flamen P, Van Cutsem E, Lerut A, et al. (2002) Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 13:361-368
31. Downey RJ, Akhurst T, Ilson D, et al. (2003) Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 21:428-432
32. Weber WA, Ott K, Becker K, et al. (2001) Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19:3058-3065
33. Young H, Baum R, Cremerius U, et al. (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35:1773-1782
34. Wagner M, Seitz U, Buck A, et al. (2003) 3′-[18F]fluoro-3′ -deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. Cancer Res 63:2681-2687
35. Buck AK, Schirrmeister H, Hetzel M, et al. (2002) 3-Deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 62:3331-3334
36. Vesselle H, Grierson J, Muzi M, et al. (2002) In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 8:3315-3323
37. Barthel H, Cleij MC, Collingridge DR, et al. (2003) 3′ -Deoxy-3′-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 63:3791-3798
38. Blankenberg FG, Strauss HW (2001) Will imaging of apoptosis play a role in clinical care? A tale of mice and men. Apoptosis 6:117-123
39. Belhocine T, Steinmetz N, Hustinx R, et al. (2002) Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res 8:2766-2774
40. Glaser M, Collingridge DR, Aboagye EO, et al. (2003) Iodine-124 labelled annexin-V as a potential radiotracer to study apoptosis using positron emission tomography. Appl Radiat Isot 58:55-62
41. Mease RC, Weinberg IN, Toretsky JA, et al. (2003) Preparation of F-18 labeled annexin V: a potential PET radiopharmaceutical for imaging cell death [abstract]. J Nucl Med 44(suppl):295P
42. Sangro B, Herraiz M, Prieto J (2003) Gene therapy of neoplastic liver diseases. Int J Biochem Cell Biol 35:135-148
43. Blasberg R (2002) PET imaging of gene expression. Eur J Cancer 38:2137-2146
44. Grosu AL, Feldmann H, Dick S, et al. (2002) Implications of IMT-SPECT for postoperative radiotherapy planning in patients with gliomas. Int J Radiat Oncol Biol Phys 54:842-854
45. Sobottka SB, Bredow J, Beuthien-Baumann B, et al. (2002) Comparison of functional brain PET images and intraoperative brain-mapping data using image-guided surgery. Comput Aided Surg 7:317-325
46. Sure U, Benes L, Riegel T, et al. (2002) Image fusion for skull base neuronavigation. Technical note. Neurol Med Chir (Tokyo) 42:458-462
47. Grosu AL, Lachner R, Wiedenmann N, et al. (2003) Validation of a method for automatic image fusion (BrainLAB System) of CT data and (11) C-methionine-PET data for stereotactic radiotherapy using a LINAC: first clinical experience. Int J Radiat Oncol Biol Phys 56: 1450-1463
48. Ung YC, Ehrlich LE, Ganguli SN (2001) 18FDG hybrid PET and CT fusion improves target volume definition in treatment planning for carcinomas of the anal canal. Int J Radiat Oncol Biol Phys 50:1416
49. Dehdashti F, Grigsby PW, Mintun MA, et al. (2003) Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys 55:1233-1238
50. Sorger D, Patt M, Kumar P, et al. (2003) [(18)F]Fluoroazomycinarabinofuranoside ((18)FAZA) and [(18)F]Fluoromisonidazole ((18)FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol 30:317-326
51. Kubota K, Tada M, Yamada S, et al. (1999) Comparison of the distribution of fluorine-18 fluoromisonidazole, deoxyglucose and methionine in tumor tissue. Eur J Nucl Med 26:750-757
52. Piert M, Machulla HJ, Reichel G, et al. (2002) Fluorine-18 labeled fluoroazomycin arabinoside (FAZA): imaging murine tumor hypoxia with improved biokinetics. J Nucl Med 43:278P
53. Chapman JD, Bradley JD, Eary JF, et al. (2003) Molecular (functional) imaging for radiotherapy applications: an RTOG symposium. Int J Radiat Oncol Biol Phys 55:294-301
54. Chao KS, Bosch WR, Mutic S, et al. (2001) A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 49:1171-1182
55. Peters KB, Brown JM (2002) Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res 62:5248-5253
56. Weber WA, Haubner R, Vabuliene E, et al. (2001) Tumor angiogenesis targeting using imaging agents. Q J Nucl Med 45:179-182
57. Haubner R, Wester HJ, Weber WA, et al. (2001) Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 61: 1781-1785
58. Janssen ML, Oyen WJ, Dijkgraaf I, et al. (2002) Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res 62:6146-6151
59. Postema EJ, Oyen WJ, Boerman OC, et al. (2003) Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody. J Nucl Med 44:853
60. Press OW, Leonard JP, Coiffier B, et al. (2001) Immunotherapy of non-Hodgkin's lymphomas. Hematology 221-240
61. Kaminski MS, Estes J, Zasadny KR, et al. (2000) Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96:1259-1266
62. Scheidhauer K, Wolf I, Baumgart HJ, et al. (2002) Biodistribution and kinetics of (131)I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 29:1276-1282
63. Cremonesi M, Ferrari M, Chinol M, et al. (2000) Dosimetry in radionuclide therapies with 90Y-conjugates: the IEO experience. Q J Nucl Med 44:325-332
64. Forster GJ, Engelbach MJ, Brockmann JJ, et al. (2001) Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide. Eur J Nucl Med 28:1743-1750
65. Wainwright S. Axis and circumference: the cylindrical shape of plants and animals. Cambridge: Harvard University Press, 1988